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1. Introduction
Therapy for central nervous system (CNS) diseases requires drugs that can cross the blood-
brain barrier (BBB) (Cheng et al, 2010). BBB not only maintains the homeostasis of the CNS, but
also refuses many potentially important diagnostic and therapeutic agents from entering into
the brain (Chen et al, 2009). The pathogenesis of Alzheimer's disease (AD) senile plaque and
neurofibrillary tangle lesions putatively involves a compromised BBB (Jevnes & Provias, 2011),
which protects the brain against endogenous and exogenous compounds and plays an important
part in the maintenance of the microenvironment of the brain (Vogelgesang et al, 2011). The
ability of drug permeating across BBB becomes critical in the development of new medicines,
especially in the design of new drugs which are active in brain tissue. In particular,  the
importance of brain-to-blood transport of brain-derived metabolites across the BBB has gained
increasing attention as  a  potential  mechanism in  the  pathogenesis  of  neurodegenerative
disorders such as Parkinson's disease (Bartels, 2011) and AD characterized by the aberrant
polymerization and accumulation of specific misfolded proteins, particularly β-amyloid (Aβ),
a neuropathological hallmark of AD. P-glycoprotein (P-gp or MDR1/ABCB1) is a 170-kDa
transmembrane protein widely expressed from the epithelial cells of the intestine, liver, kidney,
placenta, uterus, and testis to endothelial cells of the BBB (Gottesman & Pastan, 1993). It belongs
to the ABC (ATP-binding cassette) transporter family and serves to pump exogenous substan‐
ces out of the cells (Suresh et al, 1999). The domain topology of P-gp consist of two homolo‐
gous halves each consist a transmembrane domain preceding a cytosolic nucleotide binding
domain. Each transmembrane domain is composed of six transmembrane α-helix segments
involved in efflux as well as in drug binding (Kast et al, 1996). The ABC transport protein P-
gp, a major component of the BBB, mediates the efflux of Aβ from the brain as well as a major
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factor in mediating resistance to brain entry by numerous exogenous chemicals, including
therapeutic pharmaceuticals (Bendayan et al, 2002). P-gp plays a role in the etiology of AD
through the clearance of Aβ from the brain. Some drugs, such as rifampicin, dexamethasone,
caffeine, verapamil, hyperforin, β-estradiol and pentylenetetrazole, were able to improve the
efflux of Aβ from the cells via P-gp up-regulation (Abuznait et al, 2011). Meanwhile, some
compounds have been shown to reverse the P-gp mediated multidrug resistance (MDR),
including verapamil, adriamycin, cyclosporin, and dexverapamil (Kothandan et al, 2011). Harta
et al (2010) have shown that up-regulate P-gp in the early stages of AD has the potential to
increase Aβ clearance from the brain and reduce Aβ brain accumulation by a transgenic mouse
model of AD (human amyloid precursor protein-overexpressing mice). Abuznait et al (2011)
have also elucidated the impact of P-gp up-regulation on the clearance of Aβ, which indicat‐
ed targeting Aβ clearance via P-gp up-regulation effective in slowing or halting the progres‐
sion of AD and the possibility of P-gp as a potential therapeutic target for AD.
P-gp at the BBB functions as an active efflux pump by extruding a substrate from the brain,
which is important for maintaining loco-regional homeostasis in the brain and protection
against toxic compounds (Bartels, 2011). P-gp is also discovered in various resistant tumor cells
and expressed widely in many normal tissues and plays a very important role in drug ADME-
Tox (absorption, distribution, metabolism, excretion, and toxicity). MDR is a matter of growing
concern in chemotherapy. Cells which express the multidrug resistance phenotype can over-
express efflux transporters after exposure to a single agent. As a result, these cells become
resistant to the selective agent and cross-resistant to a broad spectrum of structurally and
functionally dissimilar drugs. The drug efflux pump P-gp has been shown to promote MDR
in tumors as well as to influence ADME properties of drug candidates (Jabben et al, 2012). P-
gp is expressed at the BBB, the blood-cerebrospinal fluid barrier, and the intestinal barrier,
thus modulating the absorption and excretion of xenobiotics across these barriers. P-gp and
its ligands (substrates and inhibitors) are therefore extensively studied both with respect to
reversing MDR in tumors and for modifying ADME-Tox properties of drug candidates, such
as CNS active agents (Jabben et al, 2012). P-gp possesses broad substrate specificity and
substrates include members of many clinically important therapeutic drug classes, including
anti-HIV protease inhibitors, calcium channel blockers used in the treatment of angina,
hypertension, antibiotics and cancer chemotherapeutics (Stouch & Gudmundsson, 2002). In
this active efflux process, energy originating from ATP hydrolysis is directly consumed.
Because of such a wide distribution of P-gp, so if a drug such as quinidine or verapamil inhibits
the function of P-gp, it will also inhibit the excretion of digoxin by P-gp leading to increased
plasma levels and toxicity due to digoxin. It is believed to be an important protective mecha‐
nism against environmental toxins (Martin, 2004). Since the function of P-gp always results in
lack of intracellular levels of the drug necessary for effective therapy, the overexpression of P-
gp in certain malignant cells is always associated with MDR phenotype (Sharom, 1997).
Although recently low resolution structure of P-gp is obtained, its physiological function and
mechanisms of MDR modulation are still not very clear (Li et al, 2005). It is well known that a
large number of structurally and functionally diverse compounds act as substrates or modu‐
lators of P-gp, including calcium and sodium channel blockers, calmodulin antagonists and
structural analogues, protein kinase C inhibitors, steroidal and structurally related com‐
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pounds, indole alkaloids, cyclic peptides and macrolide compounds, flayanoids and miscel‐
laneous compounds (Wang et al, 2003), which mostly share common structural features, such
as aromatic ring structures and high lipophilicity. Some of them possess MDR reversing
activity. But only a small number of them have entered clinical study and classification of
candidate drugs as substrates or inhibitors of the carrier protein is of crucial importance in
drug development (Wang et al, 2005).
On the other hand, the prerequisite to cure neurological disorders is that the drug distribution
in CNS can reach effectively therapeutic concentrations (Chen et al, 2009). Usually, the high
BBB penetration is needed for drugs that activate in brain. The molecule negotiating the BBB
must go through cellular membranes comprising of a lipid bilayer. Until now, it is widely
accepted that interaction of compounds with P-gp is a complex process and at this time the
details of its mechanism of action are still the subject on hot debate. Although the experimental
analysis of drug permeability is essential but the procedure of experiment is time consuming
and complicated, a theoretical model of drug permeability is effective to give predictions.
Membrane-interaction (MI)-QSAR (quantitative structure-activity relationship) method is a
structure-based design methodology combined with classic intramolecular QSAR analysis to
model chemically and structurally diverse compounds interacting with cellular membranes.
Our modified MI-QSAR method that combines QSAR with solute-membrane-water complex
simulating the BBB environment is more close to the body condition than MI-QSAR and
possesses higher ability to predict organic compounds across BBB (Chen & Yang, 2006). Before
we construct any QSAR models, several things should be consider seriously first. There are
several critical assumptions that can influence validity and correctness of any QSAR study as
follows: the same mechanism of action of all studied analogs; a comparable manner of their
binding to the receptor; correlation of binding to the interaction energies; correlation of
measured biological activities to the binding affinities (Kubinyi, 1995). All the accuracy answer
and research based on the questions above may guarantee that proper and reliable relation‐
ships are obtained. However, in case of MDR modulators different mechanisms and different
binding sites may be involved. Several screening assays can help in the identification of
substrates and inhibitors although they have both advantages and drawbacks, such as
cytotoxity assays (Wiese & Pajeva, 2001), inhibition of efflux assays (Stouch & Gudrmundsson,
2001), P-gp-ATPase activation assays, and drug transport assays (Taub et al, 2005).
The goal of a QSAR study is to find a means of predicting the activity of a new compound. If
possible, a desirable goal is the understanding of the biology and chemistry that give rise to
that activity and the consequential possibility of reengineering the compound to remove or
enhance that activity. One successful example is the transformation of nalidixic acid with the
help of QSAR into an important family of drug: the quinolone carboxylates, such as norflox‐
acin, fleroxacin, ciprofloxacin, and levofloxacin (Alka, 2003). Since the method was established
in the 1960s, QSAR equations have been used to describe the biological activities of thousands
of different drugs and drug candidates (Kuo et al, 2004). The method definitely provides a
more accurate way to synthesize or filtrate the new chemical compounds. At last, the final
destination is to degrade the cost of research and manufacture. To date, so many methods have
been used in QSAR study and some of them have got successful results. There are general
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methods used in the literatures these years, such as multiple linear regression (MLR) method,
partial least square regression (PLSR) (Li et al, 2005), MI-QSAR analysis (Chen & Yang, 2006),
and three-dimension (3D) QSAR (Cramer et al, 1988), and artificial neural network (ANN)
(Chen et al, 2006). In order to get more accurate results and QSAR models, we have used two
different analyses: MLR and PLSR. Moreover, we focus on constructing theoretical models of
the interaction between organic compounds and P-gp as well as the predictive models of blood-
brain barrier partitioning of organic compounds on the basis of QSAR analysis and MI-QSAR
analysis.
2. Materials and methods
2.1. P-glycoprotein ligands
Building of some compounds 36 purine derivatives were selected and used in QSAR analysis
(table 1) (Dhainaut et al, 1996). These compounds were divided into two sets: the training set
and the test set. The study of the MDR-reversing properties of these derivatives was carried
out in vitro on P388/VCR-20 cells, a murine leukemia cell line whose resistance was induced
by vincristine (VCR), and KB-A1 cells, a human epidermoid carcinoma cell line whose
resistance was induced by adriamycin (ADR). The compounds were tested at four concentra‐
tions (0.5−5 μM) in association with VCR (P388/VCR-20 cells) or ADR (KB-A1 cells). In this
test, MDR ratio in P388/VDR-20 and KB-A1 in vitro was used as biological activity for the
whole dataset, namely MDRratio =
I C50(CD)
I C50(CD + mod) . Here “CD” is the abbreviation for cytotoxic
drug (such as VCR and ADR) in cytotoxity assays, and “mod” means modulators. It is defined
as ratio between the IC50 values (concentration that inhibits the growth of MDR cells by 50%)
of the cytotoxic agent in absence and presence of relatively nontoxic concentration of the
modifier (Wiese & Pajeva, 2001). Most often the IC50 for several concentration of a cytotoxic
drug is evaluated in the presence and absence of a nontoxic concentration of a P-gp modifier.
In this assay modulators that interact with P-gp and thus, reduce the efflux of the cytotoxic
compounds, will increase the apparent toxicity of the cytotoxic compound. It is important to
keep in mind that it is based on a general assessment of cytotoxicity and thus may account for
more then one acting mechanism in the resistant cells used (Stouch & Gudmundsso,. 2001).
Furthermore, it is well known that the MDR ratio for any given compound can vary greatly
depending on the cell type used for the assay as well as the intrinsic cytotoxicity of the
compounds used. The data is also dependent on the concentration of the P-gp substrates or
modulators used in the studies (Ford et al, 1990).
Similarly, another 21 propafenone analogs were selected from the literature of Diethart Schmid
et al (1999) and used in QSAR analysis (table 2). In this test Ka of P-gp ATPase in the adria‐
mycin-resistant subline CCRF ADR5000 was used as biological activity for the whole dataset
(Schmid et al, 1999). The assays were performed based on the colorimetric determination of
inorganic phosphate released by the hydrolysis of ATP. Table 2 shows all the structures and
the experimental biological activity value.
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No. Structure in vitro reversal fold
reversion (MDR ratio)
No. Structure in vitro reversal fold
reversion (MDR ratio)
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Note: Ratio of IC50 (cytotoxic alone (VCR for P388/VCR-20, ADR for KB-A1 cells))/IC50 (cytotoxic + modulator) (1μM in
association with VCR or 2.5 μM in association with ADR) (Dhainaut et al, 1996).
Table 1. The structures and MDR ratios of 35 purine derivatives in the training/test sets.
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No. Structure Ka(μM/L) LogP No. Structure Ka(μM/L) LogP
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Table 2. The structures and Ka values and LogP of 18 propafenone analogs in the training/test sets.
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Finally, all two-dimensional structures of these compounds mentioned above were construct‐
ed using the chemical drawing software ChemDraw 8.0 and prepared for the next calculation.
Calculation of some descriptors  Molecular descriptors are “numbers that  characterize a
specific aspect of the molecular structure” (Karelson, 2000). There are a great number of
molecular descriptors that can be used in QSAR studies in the structure parameterization
form, which include physicochemical properties (such as hydrophobicity, aqueous solubili‐
ty, molecular electronegativity, and molecular refractivity), quantum chemical parameters
(i.g. atomic charges, energies of HOMO (highest occupied molecular orbital) and LUMO
(lowest unoccupied molecular orbital)) (Karelson & Lobanov, 1996), topological indexes (i.e.
molecular  connectivity  indexes)  (Ponce  et  al,  2004),  and  other  three-dimentional  (3D)
descriptors.  Molecular  descriptors  were  mostly  calculated  by  the  commercial  software
packages Chemoffice Chem3D Ultra 8.0, which included molecular mechanism parameters
(Bending Energy (Ebend), Stretch-Bend Energy (Estretch), Torsion Energy (Etorsion), Total Energy
(Etotal),  van der Waals Energy (EVDW),  etc),  quantum chemistry parameters (i.e.  Electronic
Energy (Eelectronic), HOMO Energy (EHOMO) and LUMO Energy (ELUMO)), hydrophobic param‐
eters (such as Clog P), stereo parameters (eg. Es, Balaban Index (BI), Connolly Accessible
Area (CAA), Molecular Weight (MW), Shape Attribute (ShA), Total Connectivity (Tcon), and
Wiener  Index  (WI)),  thermodynamic  parameters,  including  Henry's  Law  Constant  (H),
Hydration Energy (Ehyd), Logarithm of partition coefficient in n-octanol/water (LogP), Molar
Refractivity (MR), and molecular polar surface area (PSA). PSA is defined as the surface area
(Å2)  occupied by polar atoms, usually oxygen, nitrogen and hydrogen attached to them,
which will restrict molecule penetration into the membranes (Chen et al, 2009). The other
properties involved in number of hydrogen bond acceptor (NBA) and number of hydro‐
gen bond donor (NBD).
The energy parameters root in the results of molecular mechanism and molecular dynamics.
The total energy of a system expressed as follows (Iyer et al 2002):
Etotal = Evalence + Ecrossterm + Enonbone.
Here, the valence interactions includes bond stretching (bond), valence angle bending (angle),
dihedral angle torsion (torsion), and inversion, also called out-of-plane interactions (oop)
terms, which are part of nearly all forcefields for covalent systems. A Urey-Bradley term (UB)
may be used to account for interactions between atom pairs involved in 1-3 configurations (i.e.,
atoms bound to a common atom): Evalence = Ebond + Eangle + Etorsion + Eoop + EUP . Modern (second-
generation) forcefields generally achieve higher accuracy by including cross terms to account
for such factors as bond or angle distortions caused by nearby atoms. Crossterms can include
the following terms: stretch-stretch, stretch-bend-stretch, bend-bend, torsion-stretch, torsion-
bend-bend, bend-torsion-bend, stretch-torsion-stretch. The interaction energy between non-
bonded atoms is accounted by van der Waals (VDW), electrostatic (Coulomb), and hydrogen
bond (hbond) terms in some older forcefields. Enon−bond = EVDW + ECoulomb + Ehbond . Restraints
that can be added to an energy expression include distance, angle, torsion, and inversion
restraints. Restraints are useful if you, for example, are interested in only part of a structure
for information on restraints and their implementation and use, and also the documentation
for the particular simulation engine.
Neurodegenerative Diseases264
With the aid of Chemoffice Chem3D Ultra 8.0 and Hyperchem 7.5, we calculated the following
descriptors by the procedure in detail below: (1) Draw the structures in ChemDraw 8.0; (2)
Change structures to 3D by Chem3D; (3) Considering our chosen compounds, minimize the
energy of the molecule based on molecular mechanism MM2 Force Field (Because under the
MM2 force field, the time required for performing computations increases as N2, where N is
the number of atoms.). We have chosen the job type as minimize energy to minimum RMS
(root mean square) Gradient of 0.100 (the default value of 0.100 is a reasonable compromise
between accuracy and speed). (4) Under the menu of Analyze-compute properties, select the
properties to calculate and get every descriptor value of each compound.
QSAR models QSAR model of some purine derivatives (table 1) are achieved by partial sum
of squares for regression with software SPSS 10.0. Some biological activity data are so large or
small that the group of data cannot form a normal school, which is very important in lineal
regression, and will surely degrade the accuracy of QSAR equations. So we discarded several
data out of the normal school and some without necessary descriptors value. A training set of
26 structurally diverse purine derivatives are measured is used to construct QSAR models.
The QSAR models are optimized using MLR fitting and stepwise method (Eq.1-Eq.5). A test
set of five compounds is evaluated using the QSAR models as part of a validation process.
Take MDR ratio in vitro in P388/VDR cell lines as dependent variable and molecule descriptors
as independent variable. With the aid of Virtual Computational Chemistry Laboratory
software (Wang et al, 2005), QSAR modeling was constructed by PLSR (Eg. 6).
Similarly, a training set of 18 structurally diverse propafenone analogs (table 2) are measured
is used to construct QSAR models. The QSAR models are optimized using MLR fitting and
stepwise method (Eq.7-Eq.11). Another QSAR modeling was constructed by PLSR (Eg. 12). A
test set of five compounds is evaluated using the QSAR models as part of a validation process.
2.2. Blood-brain-barrier
Building of some compounds 37 organic compounds (Abraham et al, 1995; Abraham et al,
1997) were elected, composed a train set, and another 8 organic compounds were acted as a
test set (table 3). The dependent variable used in this predictive model is the logarithm of the
BBB partition coefficient, log BB = log (Cbrain / Cblood), where Cbrain is the concentration of the test
compound in the brain, and Cblood is the concentration of the test compound in blood. Experi‐
mental values of log BB published to date lie approximately between -2.00 to +1.04. Com‐
pounds with log BB values of > 0.30 are readily distributed to the brain whereas compounds
with values < -1.00 are poorly distributed to the brain. Building of all these compounds was
performed on a PC computer using the Build modules of the commercial software packages
Hyperchem 7.5. First, the geometry of these compounds was opitimized using the Amber 94
force field in gas state. Second, they were placed at a periodic solvent box whose volume was
X=16Å, Y=10Å, Z=18Å, which included 96 water molecules. Here, temperature is 300ºK and
pressure is 1 standard atmosphere. Then, the compounds in water were minimized by the
above method. Third, the compounds in water were simulated by Monte Carlo method and
minimized by the above method.
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No Structure LogBB No Structure LogBB
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Table 3. The structures and LogBB values of some compounds in the training/test sets.
Molecular modeling of a DMPC monolayer membrane complex with a layer of water. A
model of dimyristoylphosphatidylcholine (DMPC) monolayer membrane was constructed
using the software Material Studio, and minimized for 200 steps with the smart minimizer.
The DMPC monolayer membrane was composed of 25 DMPC molecules (5×5×1). Here, the
parameter of the single crystal of DMPC was a=8Å, b=8Å, and γ =96.0 , which resulted average
area of each lipid molecule 64Å2 similar to Stouch’s research results (Bassolino-Klimas et al,
1993). Moreover, we add a layer of water (40×40×10) including 529 water molecules to the
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polar side of the DMPC monolayer membrane. Figure 1 showed the dominant conformation
of B1 compound colored by atom-type in water. The red box denotes the water solvent box
defined in Monte Carlo simulation.
Figure 1. The dominant conformation of B1 compound colored by atom-type in water. The red box denotes the water
solvent box defined in Monte Carlo simulation.
Molecular dynamic simulation of a small molecule complex with DMPC-water model. A
DMPC molecule at the center of the above DMPC monolayer membrane complex with a layer
of water was replaced with an organic compound to form a solute-membrane-water complex.
The center organic compound was inserted at three different positions in the DMPC-water
model before the start of each of the three corresponding molecular dynamics simulation.
Molecular dynamic simulation of the complex was performed for 1000 steps by Discover
module with Materials Studios, using Compass force field. Here, the three-dimensional
volume was restricted to a border of X=40Å, Y=40Å, Z=91.76Å, and γ =96.0 .
QSAR model of BBB partitioning of some compounds. MI-QSAR model of some organic
compounds through BBB are achieved by partial sum of squares for regression with software
SPSS. A training set of 37 structurally diverse compounds whose BBB partition coefficients are
measured is used to construct QSAR models. Molecular dynamics simulations are used to
determine the explicit interaction of each test compound with a model of DMPC monolayer
membrane complex with a layer of water. An additional set of intramolecular solute descrip‐
tors are computed and considered in the trial pool of descriptors for building MI-QSAR
models. The QSAR models are optimized using multidimensional linear regression fitting and
stepwise method. A test set of eight compounds is evaluated using the MI-QSAR models as
part of a validation process.
3. Results
3.1. QSAR analysis based on MDR ratio in P388/VDR-20 and KB-A1 in vitro
Take MDR ratio in vitro in KB-A1/ADR cell lines as dependent variable and molecule descrip‐
tors as independent variable. A training set of 26 structurally diverse compounds (Table 4) was
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used to construct QSAR models. The QSAR models were optimized using MLR fitting and
stepwise method by the SPSS software (Eq.1-Eq.5). A test set of 5 compounds (compound A27-
A31) was evaluated using the models as part of a validation process (figure 2 upper, Table 5).
Meanwhile, take MDR ratio in vitro in P388/VDR cell lines as dependent variable and molecule
descriptors as independent variable. With the aid of Virtual Computational Chemistry
Laboratory software (http://vcclab.org) (Wang et al, 2005), construct QSAR modeling by PLSR
(Eg.6, figure 2 down). Table 6 shows the calculated descriptors mentioned above and the result
of predicted value was in Table 5.
 
Figure 2. Comparison of the experimental MDR values with the corresponding predicted MDR values. Upper: MDR
value in KB-A1/ADR cell lines (blue rhombic dots); MDR as predicted by Eg.4 MLR model (red square dots) and by Eg.5
MLR model (yellow triangle dots) for all the molecules of the training and test set. Down: MDR value in P388/VDR cell
lines (blue rhombic dots); MDR as predicted by the method of PLSR (Eg. 6) (red square dots) for all the molecules of
the training and test set. The rhombic dots represented the experimental values (P388) and the predicted values of
MDR, respectively.
N
6.537 7.16
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2LogMDR LogMR= - + (1)
37.830 48.862 0.49
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= = =
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0.801 4.791 10 0.369
N= 27; R= 0.936; F=29.74
3.595 10
9
LogMDR LogMR
ShA BI LogP Ehyd- -
= - + -
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2 4
2
7.611 3.138 10 0.245
N=30; Q =0
0.495
.465
0.509 8.8 10
0
02VDWLogMDR LogP MR E ShA WI- -= + ´ - + - + ´ (6)
No. Log MR ShA BI LogP Ehyd(kcal/mol) No. Log MR ShA BI LogP
Ehyd
(kcal/mol)
Training set
A1 1.20 37.03 2662570 3.33 -3.56 A14 1.22 39.02 3358755 1.48 -19.64
A2 1.18 35.03 2440928 2.59 -13.71 A15 1.22 39.02 3358755 1.48 -19.71
A3 1.22 40.02 3649082 1.14 -16.23 A16 1.20 37.03 2662570 2.13 -15.99
A4 1.14 32.03 1669953 2.21 -13.54 A17 1.202 37.03 2662570 2.13 -16.23
A5 1.22 39.02 3358755 1.33 -19.71 A18 1.202 37.03 2662570 2.13 -15.95
A6 1.20 37.03 2662570 2.13 -16.22 A19 1.18 37.03 3091919 1.61 -15.9
A7 1.22 40.02 3491392 0.76 -17.67 A20 1.23 41.02 4008723 0.76 -17.36
A8 1.20 37.03 2662570 2.28 -16.3 A21 1.14 32.03 1651352 1.9 -13.79
A9 1.24 42.02 4491514 1.29 -16.34 A22 1.22 39.02 3324212 1.33 -20.06
A10 1.24 41.02 4055919 0.99 -19.77 A23 1.20 37.03 2634052 2.13 -15.77
A11 1.18 36.03 2271976 1.41 -17.73 A24 1.19 36.03 2246188 2.13 -16.15
A12 1.19 36.03 2271976 2.13 -16.17 A25 1.15 35.03 2244801 1.71 -14.88
A13 1.15 33.03 1900460 2.28 -13.57 A26 1.15 35.03 2271261 1.71 -15.03
Test set
A27 1.19 37.03 2662570 1.41 -18.09 A30 1.25 41.02 3977672 2.98 -13.52
A28 1.22 40.02 3491392 0.76 -17.61 A31 1.20 37.03 2634052 2.13 -15.95
A29 1.21 37.03 2662570 2.75 -15.55
Table 4. The molecular descriptors of some compounds related to MDR ratios in the training/test sets
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No. MDR
ratio (KB-
A1)
Predictive values of MDR ratio No. MDR
ratio (KB-
A1)
Predictive values of MDR ratio
Eq.1 Eq.2 Eq.3 Eq.4 Eq.5 Eq.1 Eq.2 Eq.3 Eq.4 Eq.5
Training set
A1 171 114.32 215.61 200.33 123.15 180.87 A14 147 151.94 151.04 171.02 173.75 144.79
A2 278 80.79 200.54 305.22 260.52 228.39 A15 152 150.27 140.09 157.75 159.16 130.87
A3 238 161.08 71.37 78.37 79.12 92.55 A16 209 115.64 233.15 217.87 209.32 197.83
A4 236 44.84 113.11 178.94 196.99 213.61 A17 171 115.64 233.15 217.87 209.32 193.94
A5 160 150.27 140.09 157.75 168.14 148.66 A18 156 116.97 252.09 236.91 229.26 219.10
A6 208 113.02 199.36 184.18 174.42 159.21 A19 49 81.98 22.31 33.79 29.47 25.56
A7 102 163.01 77.39 67.24 80.67 105.63 A20 214 198.44 93.91 119.73 132.46 165.76
A8 120 114.32 215.61 200.33 180.88 153.75 A21 113 42.69 80.90 121.41 145.60 174.56
A9 75 237.62 101.82 179.28 149.94 146.81 A22 200 150.27 140.09 149.67 160.44 139.02
A10 136 222.49 204.96 297.19 322.30 315.82 A23 189 113.02 199.36 176.36 167.80 160.14
A11 44 79.86 58.80 41.66 49.61 53.08 A24 142 92.42 159.30 116.68 117.52 112.54
A12 83 92.42 159.30 121.35 121.70 115.60 A25 6 52.12 10.08 9.16 8.45 8.02
A13 272 53.80 124.41 185.32 190.50 197.66 A26 9 52.12 10.08 9.53 8.76 8.16
Testset
A27 406 99.21 81.97 70.98 80.61 81.67 A30 370 243.10 375.08 504.47 282.78 192.47
A28 68 163.01 77.39 67.24 80.67 106.16 A31 210 114.32 215.61 191.82 183.83 174.21
A29 723 125.69 411.51 400.76 323.36 248.59
Table 5. The experimental values and the predictive values of MDR ratio of these compounds.
No. MDR
(P388)
Pred
MDR
LogP MR EVDW ShA WI No. MDR
(P388)
Pred
MDR
LogP MR EVDW ShA WI
A1 50 43.66 3.33 15.85 32.21 37.03 5476 A18 129 62.87 2.13 15.90 27.08 37.03 5476
A2 78 40.71 2.59 15.10 21.84 35.08 4872 A19 36 29.48 1.61 15.13 21.63 37.03 5585
A3 75 53.15 1.14 16.63 24.83 40.02 6522 A20 70 73.87 0.76 17.12 25.52 41.02 6855
A4 53 55.39 2.21 13.91 20.16 32.03 3916 A21 35 54.41 1.9 13.82 20.17 32.03 3874
A6 93 86.84 2.13 15.83 32.75 37.03 5476 A24 24 24.57 2.13 15.39 23.42 36.03 4855
A8 30 47.64 2.28 15.85 25.21 37.03 5476 A25 13 11.32 1.71 14.21 22.20 35.03 4487
A9 57 79.51 1.29 17.56 26.03 42.02 7353 A26 24 11.44 1.71 14.21 20.92 35.03 4538
A10 108 138.69 0.99 17.40 29.44 41.02 6935 A27 84 58.01 1.41 15.54 26.05 37.03 5476
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No. MDR
(P388)
Pred
MDR
LogP MR EVDW ShA WI No. MDR
(P388)
Pred
MDR
LogP MR EVDW ShA WI
A11 37 30.21 1.41 15.08 24.04 36.03 4909 A28 57 35.88 0.76 16.66 23.78 40.02 6244
A12 15 27.61 2.13 15.39 23.512 36.03 4909 A29 108 49.03 2.75 16.06 25.95 37.03 5476
A13 78 87.23 2.28 14.27 29.12 33.03 4216 A30 27 35.79 2.98 17.61 26.49 41.02 6804
A14 56 96.24 1.48 16.50 28.19 39.02 6288 A32 59 30.18 1.83 15.13 22.08 37.03 5642
A15 75 89.20 1.48 16.47 27.54 39.02 6288 A33 71 73.84 0.86 15.79 27.62 38.03 5822
A16 51 54.90 2.13 15.88 25.61 37.03 5476 A34 13 31.95 2.58 15.64 25.36 37.03 5476
A17 70 54.43 2.13 15.88 25.49 37.03 5476 A35 3 12.22 1.71 14.21 20.40 35.03 4589
Table 6. Comparison of experimental value of MDR ratio with predicted value of MDR ratio by PLSR.
3.2. QSAR analysis based on Ka of ATPase in CCRF ADR5000 cell lines
Similarly, take Ka of ATPase in CCRF ADR5000 cell lines as dependent variable and molecule
descriptors as independent variable. We construct QSAR models using two methods, MLD
method (Eq.7-Eq.11) and PLSR method (Eg.12) (see figure 3).
Figure 3. Comparison of the experimental Ka value (blue rhombic dots) with the corresponding predicted Ka as pre‐
dicted by Eg.11 MLR model (red square dats) and by Eg.12 PLSR model (yellow triangle dots) for all the molecules of
the training and test.
A training set of 16 structurally diverse compounds was used to construct QSAR models. All
the molecular descriptors were calculated as Table 7. The QSAR models were optimized using
MLR fitting and stepwise method. A test set of 2 compounds was evaluated using the models
as part of a validation process. Table 8 displays the comparison of the experiment and
prediction value.
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No. LogP ShA MR EHOMO
(eV)
WI MW No. LogP ShA MR EHOMO
(eV)
WI MW
A36 3.39 21.04 9.254 -9.14 1366 312.41 A45 4.3 26.04 11.42 -9.17 2345 383.53
A37 3.62 24.04 10.55 -9.20 1949 355.48 A46 4.93 32.03 13.27 -8.24 4689 462.57
A38 3.67 25.04 10.84 -9.16 2172 367.49 A47 5.2 32.03 13.38 -8.19 4329 464.58
A39 1.42 18.05 7.86 -9.12 920 277.37 A48 4.25 26.04 11.45 -9.24 2607 383.53
A40 4.93 32.03 13.27 -8.16 4329 462.57 A49 4.52 26.04 11.59 -8.94 2367 385.55
A41 2.67 25.04 10.29 -8.15 2244 372.44 A50 4.88 27.03 12.06 -8.94 2550 399.58
A42 0.94 19.05 8.01 -9.15 1050 293.37 A51 2.38 26.04 10.99 -9.09 2400 383.49
A43 2.54 25.04 10.52 -9.20 2172 369.46 A52 3.94 25.04 10.95 -9.05 2172 369.51
A44 3.98 32.03 13.50 -9.16 4227 459.59 A53 4.93 32.03 13.27 -8.19 4509 462.57
Table 7. The molecular descriptors of some compounds related to ATPase in the training/test sets.
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No. Ka(μM/L) Predictive values of Ka No.
Ka
(μM/L) Predictive values of Ka
Eg.7 Eg.8 Eg.9 Eg.10 Eg.11 Eg.12 Eg.7 Eg.8 Eg.9 Eg.10 Eg.11 Eg.12
A36 3.34 6.07 12.75 9.37 6.43 6.14 13.57 A45 1.53 2.20 3.02 3.32 2.69 2.08 3.50
A37 5.30 4.70 6.62 7.10 6.19 5.60 7.33 A46 1.47 1.09 0.73 0.52 0.48 0.81 1.02
A38 2.59 4.44 5.41 5.36 3.98 3.06 6.24 A47 0.55 0.81 0.61 0.46 0.50 0.53 0.84
A39 122 54.54 76.92 73.09 90.64 160.46 70.37 A48 7.64 2.33 3.13 3.83 3.33 4.22 3.60
A40 0.36 1.09 0.73 0.52 0.53 0.51 1.02 A49 12.20 1.72 2.62 3.39 4.98 5.00 2.99
A41 6.13 13.54 10.43 7.17 11.79 7.23 11.56 A50 2.26 1.15 1.75 2.37 3.50 3.28 2.04
A42 120.00 93.12 89.09 81.21 80.47 99.37 80.44 A51 10.50 18.71 10.66 14.57 16.6 13.20 12.02
A43 18.50 15.65 11.36 11.73 8.26 5.56 12.59 A52 12.80 3.29 4.53 4.74 4.57 3.91 5.15
A44 1.01 3.15 1.36 2.10 1.66 2.13 1.88 A53 4.15 1.09 0.73 0.52 0.51 0.65 1.02
Table 8. Comparison the experimental values with the predictive values of Ka of these compounds.
3.3. QSAR analysis based on blood-brain barrier partitioning of organic compounds
37 organic compounds of training set and 8 compounds of test set are built and minimized,
dissolved in liquid, and are optimized by Monte Carlo method and molecular mechanism,
finally the dominant conformation of these compounds are obtained. Molecular modeling of
a small molecule complex with the membrane-water model reveals that the energy of an
organic compound inserted at the middle position in the DMPC model with a layer of water
is lower than that of the other two positions. MI-QSAR analysis has been used to develop
predictive models of some organic compounds through BBB, in part, simulating the interaction
of an organic compound with the phospholipide-rich regions of cellular membranes sur‐
rounding by a layer of water. Molecular descriptors of compounds in a training set and a test
set are listed in Table 9. Six QSAR equations were constructed based on Table 9 and were listed
as follows.
2log 0.552 1.73 10
37 0.835 0.398
BB PSA
n R S
-= - ´
= = = (13)
2log 0.229 1.70 10 0.131 log
37 0.878 0.352
BB PSA C P
n R S
-= - ´ +
= = = (14)
2 2 7log 4.965 10 1.28 10 0.211 log 6.40 10
37 0.924 0.285
BB PSA C P BI
n R S
- - -= ´ - ´ + - ´
= = = (15)
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2 2 7log 6.262 10 1.36 10 0.205 log 7.11 10 0.185
37 0.938 0.264
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n R S
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log 6.580 10 1.21 10 0.206 log 7.77 10 0.197
1.330 10
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total torsion
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E E
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= ´ - ´ + - ´ - +
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(18)
Here, n means the number of compounds in a training set, R means the correlative coefficient,
and S means the standard residual error. Log BB = log (Cbrain/Cblood). PSA means the total polar
surface area of a molecule. CLogP and BI display calculated LogP and connective index of
molecular average total distance (relative covalent radius), respectively. They come from CS
calculation. ΔEtotal and ΔEtorsion are related to interaction between an organic compound and
membrane-water model. The total energy and the torsion energy of the DMPC monolayer
membrane complex with a layer of water are -340.7589 and -1724.4164 (Kcal/mol), respectively.
ΔEtotal is the change in the total potential energy of the solute-membrane-water complex
comparing with that of the membrane-water model and so is ΔEtorsion.
No PSA (Å2) ClogP BI(Å) Estretch (Kcal/
mol)
Etotal a (Kcal/
mol)
Etorsion a (Kcal/
mol)
ΔEtotal b (Kcal/
mol)
ΔEtorsion b
(Kcal/mol)
Training set
B1 78.90 1.20 12378 -1.35503 -298.2972 -1713.1146 42.46 11.30
B2 94.00 1.99 1101758 -0.15595 -406.0803 -1789.8084 -65.32 -65.39
B3 73.00 3.80 1738650 -1.48472 -256.3021 -1703.1425 84.46 21.27
B4 87.00 1.63 1346396 -1.39112 -302.7543 -1841.5635 38.00 -117.15
B5 39.00 1.02 41807 0.58131 -226.3773 -1734.7452 114.38 -10.33
B6 26.80 3.23 305770 -0.09264 -228.2923 -1679.4604 112.47 44.96
B7 88.80 1.01 58510 0.71038 -279.0781 -1671.3414 61.68 53.07
B8 76.60 2.80 62216 -0.38334 -309.2981 -1654.6730 31.46 69.74
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No PSA (Å2) ClogP BI(Å) Estretch (Kcal/
mol)
Etotal a (Kcal/
mol)
Etorsion a (Kcal/
mol)
ΔEtotal b (Kcal/
mol)
ΔEtorsion b
(Kcal/mol)
Training set
B9 104.40 1.77 83798 -0.35599 -313.4237 -1639.9898 27.34 84.43
B10 108.80 2.00 193593 -0.52172 -548.5593 -1640.9214 -207.80 83.49
B11 47.90 2.51 352512 -0.09496 -312.1226 -1656.7465 28.64 67.67
B12 45.20 4.27 779210 0.00479 -163.8011 -1716.3101 176.96 8.11
B13 38.50 2.61 158640 -0.09491 -170.3338 -1716.7159 170.43 7.70
B14 40.00 4.28 431722 -1.30506 -247.0951 -1748.0241 93.66 -23.61
B15 39.20 5.88 766256 0.09911 -289.2825 -1735.4004 51.48 -10.98
B16 54.90 5.14 766256 -0.14215 -181.0636 -1743.6068 159.70 -19.19
B17 18.80 0.62 20863 0.18071 -331.7044 -1695.6999 9.05 28.72
B18 46.70 0.27 20264 -1.36843 -209.4697 -1644.6752 131.29 79.74
B19 44.10 2.80 190375 -2.97778 -311.9182 -1713.8942 28.84 10.52
B20 5.40 4.85 210631 -0.06079 -235.7250 -1704.3399 105.03 20.08
B21 0.00 -0.47 4 0.00000 -407.3194 -1729.3793 -66.56 -4.96
B22 0.00 2.14 972 -0.00009 -239.8807 -1675.1827 100.88 49.23
B23 23.40 0.07 213 0.00000 -160.1278 -1672.3898 180.63 52.03
B24 22.60 0.69 712 0.00000 -319.0674 -1742.6968 21.69 -18.28
B25 0.00 3.74 1899 0.00067 -282.3721 -1751.6193 58.39 -27.20
B26 0.00 3.61 1661 0.00000 -285.7132 -1731.9518 55.05 -7.54
B27 0.00 1.43 1661 -0.00008 -238.7249 -1731.3090 102.03 -6.89
B28 0.00 2.48 633 0.00003 -291.5583 -1725.7370 49.20 -1.32
B29 11.60 2.46 21380 -0.00005 -418.0323 -1682.7138 -77.27 41.70
B30 24.40 -0.24 47 0.00000 -329.3150 -1704.6187 11.44 19.80
B31 10.70 1.27 7864 -0.00002 -253.3453 -1747.7044 87.41 -23.29
B32 0.00 2.37 7322 -0.00003 -268.8335 -1714.2486 71.93 10.17
B33 0.00 3.31 931 0.02567 -353.8395 -1739.7672 -13.08 -15.35
B34 24.40 -0.24 47 0.00000 -187.4520 -1720.5500 153.31 3.87
B35 0.00 1.93 7322 -0.00003 -177.4875 -1728.8621 163.27 -4.45
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No PSA (Å2) ClogP BI(Å) Estretch (Kcal/
mol)
Etotal a (Kcal/
mol)
Etorsion a (Kcal/
mol)
ΔEtotal b (Kcal/
mol)
ΔEtorsion b
(Kcal/mol)
Training set
B36 0.00 2.64 2050 -0.02344 -220.3940 -1681.1548 120.36 43.26
B37 0.00 2.63 712 -0.00002 -231.5752 -1722.2582 109.18 2.16
Test set
T1 22.70 0.321 712 0.00000 -274.7201 -1713.7409 66.04 10.68
T2 0.00 3.738 1838 0.00000 -225.6308 -1716.6234 115.13 7.79
T3 0.00 4.267 4150 0.00000 -331.3754 -1700.6397 9.38 23.78
T4 11.30 0.870 791 0.00000 -181.5954 -1700.8447 159.16 23.57
T5 0.00 4.397 4650 0.00000 -404.2903 -1741.2420 -63.53 -16.83
T6 0.00 1.103 0 0.00000 -282.9386 -1746.1889 57.82 -21.77
T7 0.00 3.339 791 0.00063 -271.9174 -1681.9440 68.84 42.47
T8 22.70 -0.208 213 0.00000 -364.8884 -1695.3605 -24.13 29.06
Note: a Etotal and Etorsion mean the total energy and the torsion energy of the complex with an organic compound and
DMPC monolayer membrane. b The total energy and the torsion energy of the DMPC monolayer membrane are
-340.758901 and -1724.416387 (Kcal/mol). ΔEtotal and ΔEtorsion are the residues between a complex of an organic
compound with DMPC monolayer membrane and the DMPC monolayer membrane.
Table 9. The molecular descriptors of the compounds related to BBB in the training/test sets
With the increase of the variable from one to six, the relativity of QSAR equation is also
improved, and the predictive ability of the model is enhanced. Eq.18 is most significant, which
means that the capability of an organic compound through BBB depends upon PSA, ClogP,
BI, Estretch, ΔEtotal, and ΔEtorsion. Moreover, the potential of an organic compound through BBB is
directly proportional to ClogP and ΔEtotal, but inversely proportional to PSA, BI, Estretch, and
ΔEtorsion. The observed and predicted log BB values of the training set compounds are listed in
Table 10. Figure 4 shows the comparison of the experimental log BB values for all the molecules
of the training set with the corresponding predicted log BB as predicted by Eg.17 and -18 MI-
QSAR models. Compound B18 in the training set is predicted to have a much higher log BB
than observed, and this molecule has also been identified as an outlier in other studies (Iyer
et al, 2002). Protonation of the molecule could account for its low log BB value.
A test set of eight solute compounds was constructed as one way to attempt to validate the
QSAR models given by six equations mentioned. The test set compounds were selected so as
to span almost the entire range in BBB partitioning. The observed and predicted log BB values
for this test set are given in Table 10 and plotted in Figure 4 (right). It seems to suggest that Eg.
17and -18 QSAR models could predict log BB for other compounds in drug design.
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No LogBB
Predictive Value of logBB
No LogBB
Predictive Value of logBB
Eg.13 Eg.14 Eg.15 Eg.16 Eg.17 Eg.18 Eg.13 Eg.14 Eg.15 Eg.16 Eg.17 Eg.18
Training set
B1 -0.04 -0.81 -0.95 -0.71 -0.52 -0.33 -0.20 B20 0.85 0.46 0.77 0.87 0.85 0.99 1.01
B2 -2.00 -1.07 -1.11 -1.44 -1.56 -1.57 -1.39 B21 0.03 0.55 0.17 -0.05 -0.03 -0.12 -0.10
B3 -1.30 -0.71 -0.51 -1.20 -1.11 -0.98 -1.17 B22 0.37 0.55 0.51 0.50 0.50 0.64 0.57
B4 -1.06 -0.95 -1.04 -1.58 -1.49 -1.37 -1.13 B23 -0.15 0.15 -0.16 -0.23 -0.24 0.04 -0.03
B5 0.11 -0.12 -0.30 -0.26 -0.40 -0.19 -0.06 B24 -0.17 0.16 -0.06 -0.09 -0.10 -0.04 0.08
B6 0.49 0.09 0.20 0.19 0.16 0.34 0.28 B25 0.97 0.55 0.72 0.84 0.83 0.91 1.07
B7 -1.17 -0.98 -1.15 -0.91 -1.11 -0.90 -0.86 B26 1.04 0.55 0.70 0.81 0.80 0.88 0.98
B8 -0.18 -0.77 -0.71 -0.38 -0.38 -0.22 -0.22 B27 0.08 0.55 0.42 0.35 0.35 0.49 0.56
B9 -1.15 -1.25 -1.31 -0.97 -0.99 -0.79 -0.81 B28 0.40 0.55 0.55 0.57 0.57 0.64 0.71
B10 -1.57 -1.33 -1.36 -1.05 -1.05 -1.16 -1.20 B29 0.24 0.35 0.35 0.41 0.39 0.31 0.27
B11 -0.46 -0.28 -0.26 -0.26 -0.31 -0.21 -0.32 B30 -0.16 0.13 -0.22 -0.31 -0.32 -0.26 -0.26
B12 -0.24 -0.23 0.02 -0.13 -0.23 0.03 0.04 B31 0.13 0.37 0.21 0.18 0.17 0.31 0.43
B13 -0.02 -0.11 -0.08 0.01 -0.02 0.26 0.34 B32 0.35 0.55 0.54 0.55 0.54 0.64 0.68
B14 0.44 -0.14 0.11 0.17 0.33 0.51 0.64 B33 0.93 0.55 0.66 0.75 0.74 0.73 0.84
B15 0.14 -0.13 0.33 0.30 0.17 0.26 0.33 B34 -0.16 0.13 -0.22 -0.31 -0.32 -0.07 -0.02
B16 0.22 -0.40 -0.03 -0.06 -0.15 0.10 0.22 B35 0.27 0.55 0.48 0.45 0.45 0.68 0.74
B17 -0.06 0.23 -0.01 -0.07 -0.11 -0.07 -0.09 B36 0.37 0.55 0.57 0.61 0.61 0.77 0.72
B18 -1.40 -0.26 -0.53 -0.50 -0.28 -0.02 -0.14 B37 0.34 0.55 0.57 0.60 0.60 0.75 0.81
B19 0.25 -0.21 -0.15 -0.05 0.45 0.59 0.62
Test set
T1 -0.08 0.16 -0.11 -0.17 -0.18 -0.06 -0.02 T5 0.81 0.55 0.81 0.97 0.96 0.88 1.02
T2 1.01 0.55 0.72 0.84 0.83 0.99 1.05 T6 0.04 0.55 0.37 0.28 0.29 0.37 0.47
T3 0.90 0.55 0.79 0.95 0.93 0.95 0.98 T7 0.76 0.55 0.67 0.75 0.75 0.84 0.81
T4 0.00 0.36 0.15 0.09 0.09 0.32 0.32 T8 -0.15 0.16 -0.18 -0.28 -0.29 -0.28 -0.31
Table 10. The experimental values and the predictive values of LogBB of these compounds.
Neurodegenerative Diseases278
 Figure 4. Comparison of the experimental log BB values (blue rhombic dots) for all the molecules of the training sets
(upper) or the test set (down) to the corresponding predicted log BB as predicted by Eg.17 MI-QSAR model (red
square dots) and by Eg.18 MI-QSAR model (yellow triangle dots).
4. Discussion
We have built some predictive models of MDR, Ka and BBB partitioning of organic compounds
by simulating the interaction of modulators or drugs interact with P-gp and/or of an organic
compound with the phospholipide-rich regions of cellular membranes. As we know in the
introduction part, modulators or drugs interact with P-gp and thus reduce the efflux of the
cytotoxic compounds will increase the apparent toxicity of the cytotoxic compounds. It is very
important to keep in mind that it is based on a general assessment of cytotoxicity and thus may
account for more than one acting mechanism in the resistant cells used. So there are many
uncertainty factors in the MDR ratio assay method and it is also convinced by our linear
regression models. Our research results using two different statistic methods, MLR and PLSR,
have revealed that the QSAR equation was also improved and the predictive ability of the
models was enhanced with the increase of the variable. Eg.5 is built on KB-A1 cell line with a
cytotoxic compound of 2.5μM ADR while Eg.6 is based on P388/VDR-20 cell line with 1.5μM
VCR. Here, most of the models gave satisfactory cross-validated Q2 above 0.500, conventional
R above 0.800 and less SE values indicating their proper predictive ability. Significant differ‐
ences between values were examined using two-tailed paired T test provided by SPSS. All the
results were considered not significant if P<0.05. Eg.5 model is the most significant and
indicated that the capability of P-gp modulators interacted with P-gp depends upon MR, BI,
Ehyd, ShA, and LogP. The former three display positive contributions to the MDR activity of P-
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gp, suggesting that the MDR activity increase accordingly with MR increase. The latter two
displays negative contribution to the MDR activity of P-gp.
On the other hand, we have built the predicted models for Ka of ATPase of some compounds
using the same statistic methods in order to get a more accurate model. Both models, Eg.11 by
MLR and Eg.12 by PLSR, point out that LogP and EHOMO are both important parameters with
the affinity for and simulation of the P-gp ATPase. LogP is negative related with the activity
of P-gp ATPase, suggesting that the ATPase activity also decrease with the increase of LogP.
Figure 3 showed that molecular A39 and A42 have higher Ka value of ATPase and is a
departure from other compounds. This may be because they have lower lipophilicity, which
is supported by the research results of Diethart Schmid et al (1999). Another significant
descriptor EHOMO is positive related with the activity of P-gp ATPase.
In another aspect, BBB partitioning is mainly found to depend upon two parameters, namely
PSA and ClogP. With the increase of the variable, the relativity of QSAR equation is also im‐
proved, and the predictive ability of the model is enhanced, especially Eq.18 most significant.
Moreover, the BBB partitioning measures of the test set compounds were predicted with the
same accuracy as the compounds of the training set. The family of these QSAR models reveal
that the capability of BBB partitioning of an organic compound focus on six significant fea‐
tures, which are PSA, ClogP, BI, Estretch, ΔEtotal, and ΔEtorsion (Eg. 18). Obviously, two of the six
descriptors of the QSAR models have positive regression coefficients and the other four de‐
scriptors  have  negative  regression  coefficients.  The  potential  of  an  organic  compound
through BBB is directly proportional to ClogP and ΔEtotal, but inversely proportional to PSA,
BI, Estretch, and ΔEtorsion. Moreover, PSA descriptor is found as a dominant descriptor in these
QSAR models, which related to the aqueous solubility of the solute compound along with a
direct lipophilicity descriptor (Clark et al, 1999). When the value of PSA of a molecule lessens
within the range from 0 to 108.80 Å2, its value of LogBB will increase. This is consistent with
the experimental results that the more polarity it possesses, the more difficultly a molecule
enters the hydrophobic environment of BBB (Stouch, 1993). BI is the connective index of mo‐
lecular average total distance, which pertains to the volume parameter. Our research result
points it out that with the accretion of its bulk, a molecule more and more difficultly across
through BBB by diffusion. However, the value of LogBB of a molecule increases with the in‐
crease of ClogP. It means that the hydrophobic molecule can pass through BBB more easily
than the hydrophilic molecule does, which is supported by the experimental results (Kalis‐
zan & Markuszewski, 1996). The presence of Estretch descriptor suggests that with the decrease
of the stretch-bend energy of a molecule, its value of LogBB increases. Two of the descriptors,
found in the log BB QSAR models (Eg.17 and Eq.18), reflect the behavior of the solute in the
membrane and the entire membrane-solute complex. Along with the meaning mentioned,
ΔEtotal is equivalent to the change in average total potential energy between the triple member
complex and the double member complex. Similarly, ΔEtorsion is the difference between the di‐
hedral torsion energy of the triple complex and that of the double complex. Here, the more
the change value of ΔEtotal is, the more its value of LogBB increases. This is because small mol‐
ecule across BBB membrane leads to the change of the structure of the complex. The more
changeability of the structure results in greater change of total potential energy, while the ac‐
cretion of the energy change is the important cause of the increase of the capability of a small
molecule through BBB. On the contrary, the less the difference of the torsion energy is, the
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larger its value of LogBB is. It displays that a small molecule tight combining with the mem‐
brane-water complex leads to increase its value of LogBB. And the relationship would sug‐
gest  that  as  the  solute  becomes  more  flexible  within  the  membrane-water  complex,  the
greater would be its log BB value, which is in agreement with the research results of Iyer M et
al (2002).
Several non-MI-QSAR computational models to describe and predict BBB partitioning have
been reported that includes other descriptors besides PSA and ClogP (Lombardo et al, 1996;
Keseru & Molnar, 2001; Crivori et al, 2000). An alternative, complementary approach to BBB
partitioning prediction uses MI-QSAR analysis developed by Iyer M et al (2002). Their research
results show that BBB partitioning of an organic compound depend upon PSA, CLogP, and
the conformational flexibility of the compounds as well as the strength of their “binding” to
the model biologic membrane. The MI-QSAR models indicate that BBB partitioning process
can be reliably described for structurally diverse molecules provided interactions of the
molecule with the phospholipide-rich regions of cellular membranes are explicitly considered.
An extension of these approaches that combines QSAR with solute-membrane-water complex
has been developed by us, which is addition of a layer of water on the hydrophilic side of
DMPC monolayer membrane in our research. And so, it is more analogous to the truth BBB
environment. Our results reveal that the distribution of organic molecules through BBB was
not only influenced by the properties of organic solutes, but also related to the property of the
solute-membrane-water complex. The former involves the polarity, hydrophobic, size, and
conformational freedom degree of organic molecules. The latter deals with the strength of an
organic molecule combined with BBB membrane and the structural changeability of a solute-
membrane-water complex. Furthermore, the capability of a small molecule across BBB is
mainly related to four physicochemical factors, which depend on the relative polarity of a small
molecule, the molecular volume, the strength of a small molecule combined with DMPC-water
model, and the changeability of the structure of a solute-membrane-water complex. The
relative polarity of a small molecule includes two parameters, namely PSA and ClogP. The
QSAR model shows that less polarity and more hydrophobic molecules relatively easily pass
through BBB and enter brain to cure. The molecular volume involves one parameter, namely
BI. The strength of a small molecule combined with DMPC monolayer membrane complex
with a layer of water involves one parameter, namely ΔEtorsion. The changeability of the
structure of a complex between a small molecule and the membrane-water complex includes
one parameter, namely ΔEtotal. The reason for the change of total energy is that small molecule
across BBB membrane leads to the change of the structure of the solute-membrane-water
complex. The more the changeability of the complex structure is, the more the change value
of total energy is, and the more easily a small molecule penetrates BBB.
Cerebral clearance of Aβ is considered to occur via elimination across BBB, as well as proteo‐
lytic degradation. Attenuation of its elimination is likely to result in increased cerebral Aβ
deposition, which may facilitate progression of AD (Ohtsuki et al, 2010). P-gp detoxifies cells
by exporting hundreds of chemically unrelated toxins but has been implicated in MDR in the
treatment of cancers. Substrate promiscuity is a hallmark of P-gp activity, thus a structural
description of poly-specific drug-binding is important for the rational design of anti-amyloid
accumulation drugs, anticancer drugs and MDR inhibitors. The x-ray structure of apo P-gp at
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3.8 angstroms reveals an internal cavity of approximately 6000 angstroms cubed with a 30
angstrom separation of the two nucleotide-binding domains. Two additional P-gp structures
with cyclic peptide inhibitors demonstrate distinct drug-binding sites in the internal cavity
capable of stereoselectivity that is based on hydrophobic and aromatic interactions. Apo and
drug-bound P-gp structures have portals open to the cytoplasm and the inner leaflet of the
lipid bilayer for drug entry. The inward-facing conformation represents an initial stage of the
transport cycle that is competent for drug binding (Aller et al, 2009). Currently, P-gp is
identificated as an energy-dependent pump, ATPase activity as an assay in itself is possibly
problematical cause it is based upon one assumption that drug-induced ATP hydrolysis
reflects transport by the transporter (Stouch & Gudmundsson, 2001). There may be many ways
in which this activity could be altered, including direct action on the ATP binding domain.
Scientists once observed some compounds such as daunomycin and vinblastine inhibit ATPase
activity, but increase in others, suggesting that modulation of ATPase activity is highly
dependent on experimental conditions and may not correlate well with the ability of P-gp to
transport the drug (Ambudkar et al, 1992; Shapiro & Ling, 1994; Doige et al, 1993). The work
of Litman et al was one of the few studies suggesting that affinity between drugs and ATPase
activity has no correlation to LogP, but Surface Area (Litman et al, 1997). Because of the less
comparability of molecular structures in a training set, our QSAR equation possesses universal
significance. However, the precision of QSAR equation is so low that there is still a distance
to its application. So a series of organic compounds with similar structures are chosen and
consist of a training set, thus the precision of QSAR simulation is largely increased, while the
prediction of the analogues through BBB is greatly improved.
5. Conclusion
P-gp is involved in MDR and in neurodegenerative disorders such as Parkinson disease, AD
and epilepsy. The xenobiotic efflux pump P-gp limits intracellular drug accumulation by active
extrusion of compounds out of cells. P-gp mediates the efflux of Aβ from the brain together
with mediating MDR, while P-gp transports neutral or positively-charged hydrophobic
substrates with consuming energy from ATP hydrolysis. We have built up theoretical models
of the interaction between organic compounds and P-gp and compounds with the affinity for
and simulation of the P-gp ATPase. The interaction between compounds and p-gp (P-gp
binding or MDR-reversal activity of compounds) is found to depend on LogP, LogMR, and
ShA of compounds it transports, which proportional to LogMR while inversely proportional
to LogP and ShA (see Eg.1 to Eg.5). Until now we have not convinced that ATPase activity of
P-gp is well correlated with the ability of P-gp to transport the drugs. However, our constructed
model based on the analogies of purine and propafenone analogs suggests that the enzyme
hydrolysis of these compounds largely depends on LogP, MR, ShA, MW and EHOMO, especially
positive related to MR but negative to LogP and ShA (see Eg.7 to Eq.11). This shows that the
P-gp binding capacity of these compounds shares common characteristics with their ATPase
hydrolysis, namely their hydrophobic parameters (such as log P) and steric parameters (eg.
MW, ShA, MR, and WI).
Neurodegenerative Diseases282
Additionally, our constructed MI-QSAR model indicates that the distribution of organic
molecules through BBB was not only influenced by organic solutes themselves, but also related
to the properties of the solute-membrane water complex, namely interactions of the molecule
with the phospholipide-rich regions of cellular membranes. Moreover, our results reveal that
the ability of organic molecules permeating across BBB is proportional to LogP but inversely
proportional to PSA (see Eg.13 to 18), which is consistent with the research results of Chen and
co-worker (2009), namely the increasing PSA decreased LogBB rapidly while LogP positively
related to LogBB. It indicates that molecules with higher lipophilic will be partitioned into the
lipid bilayer more easily with more chances to penetrate BBB, supported by the research result
of Wang et al (2003), namely a large number of structurally and functionally diverse com‐
pounds as substrates or modulators of P-gp mostly sharing common structural features, such
as aromatic ring structures and high lipophilicity. PSA of CNS active drug should be lower
than 90 Å2 (Chen et al, 2009), while the penetration through the BBB is optimal for LogP value
in the range 1.5–2.7 (Norinder & Haeberlein, 2002).
In comparison with the ability of organic molecules permeating across BBB, P-gp binding or
MDR-reversal activity of compounds has a negative correlation with LogP. There are two
reasons for this phenomenon. Firstly, the compounds with higher liposolubility are more
vulnerable to cytochrome P450 metabolism, leading to faster clearance (Waterhouse, 2003).
P450 enzymes (CYP450s) catalyze the metabolism of a wide variety of endogenous and
Scheme 1. Flowchart for QSAR analysis of some substrates of P-glycoprotein targeting β-amyloid clearance.
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exogenous compounds including xenobiotics, drugs, environmental toxins, steroids, and fatty
acids. Aminated thioxanthones have recently been reported as P-gp inhibitors as well as its
interaction with cytochrome P450 3A4 (CYP3A4), as many substrates of P-glycoprotein and
CYP3A4 are common (Palmeira et al, 2012). The second reason is related to the mechanism of
P-gp action. According to model proposed by Higgins and Gottesman (1992), after entering
into the phospholipid bilayer, compound may interact with P-gp in the inner leaflet of the lipid
bilayer. Upon interaction with P-gp, the compound is flipped from the inner leaflet to the outer
leaflet of the lipid bilayer. The lipophilic compounds with high LogP enter into cellular
membrane easily and intend to retain there, so its opportunity to interact with P-gp increases.
The LogP not only offers opportunity to penetrate the lipid bilayer, but also gives favorable
contribution to binding with protein, such as P450, P-gp.
In conclusion, the predictive model of BBB partitioning of organic compounds contributes to
discovery of some molecules through BBB as potential AD therapeutic drugs. Moreover, the
interaction model of P-gp and modulators for treatment of multidrug resistance indicates
discovery of some molecules to increase Aβ clearance from the brain and reduce Aβ brain
accumulation by regulate BBB P-gp in the early stages of AD. The mechanism suggests new
therapeutic strategy in AD.
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